TORRANCE, Calif.–(BUSINESS WIRE)– Emmaus
Life Sciences, Inc. (Emmaus), a leader in sickle cell disease
treatment, announced today that its CEO, Yutaka Niihara, MD, MPH will
present at the 30th Annual Piper Jaffray Healthcare
Conference on Wednesday, November 28, 2018, at 8:50 a.m. ET in New York,
New York. A webcast of the event will be available at https://bit.ly/2P49yYl.
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the
discovery, development and commercialization of innovative treatments
and therapies primarily for rare and orphan disease. Its lead product,
EndariTM (L-glutamine oral powder), demonstrated positive
clinical results in the completed Phase 3 clinical trial for sickle cell
anemia and sickle ß0-thalassemia and has received U.S. FDA approval.
LaVoie Health Science
Katie Gallagher, 617-374-8800 x109
Source: Emmaus Life Sciences, Inc.